Acadia Pharma (ACAD) Tops Q3 EPS by 6c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $28.61 +1.31%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of $0.20, $0.06 better than the analyst estimate of $0.14. Revenue for the quarter came in at $250.4 million versus the consensus estimate of $248.6 million.
GUIDANCE:
Acadia Pharma sees FY2024 revenue of $940-960 million, versus the consensus of $952.5 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- China retail sales growth slows to 0.6% in July, Macquarie comments
- Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
